CRISPR Therapeutics AG Cash Flow Statement
CRSP / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
CRISPR Therapeutics AG used $345M in operating cash flow and negative free cash flow of $346M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$581.6M | -$366.3M | -$153.6M | -$650.2M | $377.7M | -$348.9M | $66.9M | -$165.0M | -$68.4M | -$23.2M | -$25.5M | -$7.0M |
| Depreciation & Amortization | $19.5M | $19.3M | $19.8M | $24.2M | $18.0M | $9.2M | $4.7M | $3.5M | $3.0M | $925.0K | $127.0K | $38.0K |
| Operating Cash Flow | -$345.0M | -$142.8M | -$260.4M | -$495.7M | $539.0M | -$238.4M | $56.7M | -$96.2M | -$70.1M | -$52.9M | $59.4M | -$4.8M |
| Capital Expenditures | $914.0K | $1.9M | $9.5M | $37.2M | $81.7M | $18.4M | $6.7M | $2.8M | $7.8M | $3.0M | $1.2M | - |
| Free Cash Flow | -$345.9M | -$144.7M | -$269.8M | -$532.9M | $457.3M | -$256.7M | $50.0M | -$99.0M | -$77.9M | -$55.9M | $58.3M | - |
| Share Buybacks | - | - | - | - | - | - | - | $57.0K | - | - | - | - |
| FCF Margin | -9855.5% | -387.7% | -72.7% | -44484.9% | 50.0% | -35705.7% | 15241.8% | -3169.4% | -190.0% | -1082.0% | - | - |